Minimal manifestation status and prednisone withdrawal in the MGTX trial

Amelia Evoli, Ikjae Lee, Hui-Chien Kuo, Inmaculada B. Aban, Gary R. Cutter, Tarrant Mcpherson, Henry J. Kaminski, Jon Sussman, Philipp Ströbel, Joel Oger, Gabriel Cea, Jeannine M. Heckmann, Wilfred Nix, Emma Ciafaloni, Giovanni Antonini, Rawiphan Witoonpanich, John O. King, Said R. Beydoun, Colin H. Chalk, Alexandru C. BarboiAnthony A. Amato, Aziz I. Shaibani, Bashar Katirji, Bryan R F Lecky, Camilla Buckley, Angela Vincent, Elza Dias-Tosta, Hiroaki Yoshikawa, Marcia Waddington-Cruz, Michael T. Pulley, Michael H. Rivner, Anna Kostera-Pruszczyk, Robert M. Pascuzzi, Carlayne E. Jackson, Jan J G Verschuuren, Janice M. Massey, John T. Kissel, Lineu C. Werneck, Michael Benatar, Richard J. Barohn, Rup Tandan, Tahseen Mozaffar, Robin Conwit, Greg Minisman, Joshua R. Sonett, Gil I. Wolfe

Risultato della ricerca: Contributo in rivistaArticolo in rivista

1 Citazioni (Scopus)

Abstract

OBJECTIVE: To examine whether sustained minimal manifestation status (MMS) with complete withdrawal of prednisone is better achieved in thymectomized patients with myasthenia gravis (MG). METHODS: This study is a post hoc analysis of data from a randomized trial of thymectomy in MG (Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy [MGTX]). MGTX was a multicenter, randomized, rater-blinded 3-year trial that was followed by a voluntary 2-year extension for patients with acetylcholine receptor (AChR) antibody-positive MG without thymoma. Patients were randomized 1:1 to thymectomy plus prednisone vs prednisone alone. Participants were age 18-65 years at enrollment with disease duration less than 5 years. All patients received oral prednisone titrated up to 100 mg on alternate days until they achieved MMS, which prompted a standardized prednisone taper as long as MMS was maintained. The achievement rate of sustained MMS (no symptoms of MG for 6 months) with complete withdrawal of prednisone was compared between the thymectomy plus prednisone and prednisone alone groups. RESULTS: Patients with MG in the thymectomy plus prednisone group achieved sustained MMS with complete withdrawal of prednisone more frequently (64% vs 38%) and quickly compared to the prednisone alone group (median time 30 months vs no median time achieved, p < 0.001) over the 5-year study period. Prednisone-associated adverse symptoms were more frequent in the prednisone alone group and distress level increased with higher doses of prednisone. CONCLUSIONS: Thymectomy benefits patients with MG by increasing the likelihood of achieving sustained MMS with complete withdrawal of prednisone. CLINICALTRIALSGOV IDENTIFIER: NCT00294658. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with generalized MG with AChR antibody, those receiving thymectomy plus prednisone are more likely to attain sustained MMS and complete prednisone withdrawal than those on prednisone alone.
Lingua originaleEnglish
pagine (da-a)e755-e766
Numero di pagine11
RivistaNeurology
Volume95
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • Adolescent
  • Thymectomy
  • Animals
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunosuppressive Agents
  • Male
  • Middle Aged
  • Myasthenia Gravis
  • Prednisone
  • Rats
  • Single-Blind Method
  • Substance Withdrawal Syndrome
  • Thymoma
  • Thymus Neoplasms
  • Young Adult
  • Adult

Fingerprint Entra nei temi di ricerca di 'Minimal manifestation status and prednisone withdrawal in the MGTX trial'. Insieme formano una fingerprint unica.

Cita questo